| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PNMA1 |
| Uniprot No | Q8ND90 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-353aa |
| 氨基酸序列 | MAMTLLEDWCRGMDVNSQRALLVWGIPVNCDEAEIEETLQAAMPQVSYRMLGRMFWREENAKAALLELTGAVDYAAIPREMPGKGGVWKVLFKPPTSDAEFLERLHLFLAREGWTVQDVARVLGFQNPTPTPGPEMPAEMLNYILDNVIQPLVESIWYKRLTLFSGRDIPGPGEETFDPWLEHTNEVLEEWQVSDVEKRRRLMESLRGPAADVIRILKSNNPAITTAECLKALEQVFGSVESSRDAQIKFLNTYQNPGEKLSAYVIRLEPLLQKVVEKGAIDKDNVNQARLEQVIAGANHSGAIRRQLWLTGAGEGPAPNLFQLLVQIREEEAKEEEEEAEATLLQLGLEGHF |
| 预测分子量 | 46.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **PNMA1重组蛋白** 的参考文献示例(内容为虚构，仅供格式参考)：
---
1. **文献名称**：*Recombinant PNMA1 Expression and Its Role in Autoimmune Neurological Disorders*
**作者**：Darnell RB, et al.
**摘要**：研究利用大肠杆菌系统表达重组PNMA1蛋白，验证其在副肿瘤性神经系统综合征中作为自身抗原的免疫反应性，证实患者血清中特异性抗体的存在。
2. **文献名称**：*Structural Characterization of Recombinant PNMA1 Using Cryo-EM*
**作者**：Schulte AM, et al.
**摘要**：通过冷冻电镜解析重组PNMA1蛋白的三维结构，揭示其可能的神经元细胞靶向机制，并探讨与癌症相关突变的关联性。
3. **文献名称**：*Functional Analysis of PNMA1 in Apoptosis via Recombinant Protein Overexpression*
**作者**：Lee C, et al.
**摘要**：在哺乳动物细胞中过表达重组PNMA1蛋白，证明其通过线粒体途径调控细胞凋亡，并可能参与神经退行性病变的病理过程。
4. **文献名称**：*Development of a PNMA1 Recombinant Protein-Based Diagnostic Assay for Paraneoplastic Antibodies*
**作者**：Zhang Y, et al.
**摘要**：建立基于重组PNMA1蛋白的ELISA检测方法，用于快速筛查副肿瘤综合征患者血清中的特异性抗体，提高临床诊断效率。
---
(注：以上文献信息为模拟生成，实际研究中请查阅真实数据库如PubMed、Web of Science等获取准确信息。)
PNMA1 (Paraneoplastic Ma Antigen 1) is a member of the PNMA gene family, initially identified for its association with paraneoplastic neurological syndromes (PNS). These rare autoimmune disorders arise when tumors outside the nervous system express proteins typically restricted to neurons, triggering cross-reactive immune responses that damage neural tissues. PNMA1 encodes a conserved neuronal protein implicated in neurodevelopment and synaptic function. Structurally, it contains a MATH (Meprin and TRAF Homology) domain, suggesting potential roles in protein-protein interactions or signaling pathways.
Recombinant PNMA1 protein is produced through genetic engineering, often using bacterial or mammalian expression systems, to enable controlled studies of its biological functions. Research has linked PNMA1 to neurodevelopmental processes, including neurite outgrowth and neuronal differentiation, though its precise molecular mechanisms remain unclear. Aberrant PNMA1 expression has been observed in cancers (e.g., gliomas, lung cancer) and neurodegenerative conditions (e.g., Alzheimer’s disease), highlighting its dual role in physiology and pathology. In cancer, PNMA1 may act as a cancer-testis antigen, normally expressed in germ cells but re-expressed in malignancies, potentially serving as an immunotherapy target.
Recombinant PNMA1 is widely used to generate antibodies for diagnostic assays, investigate protein interactions in neurological disorders, and explore its immunogenicity in PNS models. Its study also contributes to understanding autoimmune targeting of neuronal antigens and developing therapeutic strategies. Despite progress, questions persist regarding its endogenous ligands, signaling partners, and tissue-specific regulation. Further research on recombinant PNMA1 could clarify its contributions to neural plasticity, tumor immunology, and neurodegenerative cascades.
×
